CHA2DS2-VASc Score Predicts In-Hospital and Long-Term Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Who Were Undergoing Primary Percutaneous Coronary Intervention


Bozbay M., Uyarel H., Cicek G., ÖZ A., Keskin M., Murat A., ...Daha Fazla

Clinical and Applied Thrombosis/Hemostasis, cilt.23, sa.2, ss.132-138, 2017 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 2
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1177/1076029616646874
  • Dergi Adı: Clinical and Applied Thrombosis/Hemostasis
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.132-138
  • Anahtar Kelimeler: CHA(2)DS(2)-VASc score, myocardial infarction, long-term, mortality
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

CHA2DS2-VASc score includes similar risk factors for coronary artery disease. We hypothesized that admission CHA2DS2-VASc score might be predictive of adverse clinical outcomes for patients with ST-segment elevation myocardial infarction (STEMI) who were undergoing primary percutaneous coronary intervention. A total of 647 patients with STEMI enrolled in this study. The study population was divided into 2 groups according to their admission CHA2DS2-VASc score. The low group (n = 521) was defined as CHA2DS2-VASc score ≤2, and the high group (n = 126) was defined as CHA2DS2-VASc score >2. Patients in the high group had significantly higher incidence of in-hospital cardiovascular mortality (8.7% vs 1.9%; P <.001). Long-term mortality was significantly frequent in the high group (13.4% vs 3.6%, P <.001). Hypertension, admission CHA2DS2-VASc score, and Killip class >1 were independent predictors of long-term mortality. Admission CHA2DS2-VASc score >2 was identified as an effective cutoff point for long-term mortality (area under curve = 0.821; 95% confidence interval: 0.76-0.89; P <.001). CHA2DS2-VASc score is a simple, very useful, easily remembered bedside score for predicting in-hospital and long-term adverse clinical outcomes in STEMI.